P
Philippe Saiag
Researcher at Versailles Saint-Quentin-en-Yvelines University
Publications - 268
Citations - 11351
Philippe Saiag is an academic researcher from Versailles Saint-Quentin-en-Yvelines University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 47, co-authored 232 publications receiving 9406 citations. Previous affiliations of Philippe Saiag include University of Paris & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana,Anthony Ormerod,Philippe Saiag,Catherine H. Smith,Ph.I. Spuls,Alexander Nast,Jonathan Barker,Jan D. Bos,GR Burmester,Sergio Chimenti,L Dubertret,Bernadette Eberlein,R. Erdmann,J. Ferguson,Giampiero Girolomoni,Paolo Gisondi,Alessandro Giunta,Christopher E.M. Griffiths,Herbert Hönigsmann,Munther Hussain,Ray Jobling,SL Karvonen,Lajos Kemény,Ina Kopp,C. Leonardi,Mara Maccarone,Alan Menter,Ulrich Mrowietz,Luigi Naldi,Tamar Nijsten,Ortonne Jp,Hans-Dieter Orzechowski,Taina Rantanen,Kristian Reich,Natalie Reytan,H Richards,H.B. Thio,P.C.M. van de Kerkhof,B. Rzany +38 more
TL;DR: Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
Journal ArticleDOI
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012
Claus Garbe,Ketty Peris,Axel Hauschild,Philippe Saiag,Mark R. Middleton,Alan Spatz,Jean-Jacques Grob,Josep Malvehy,Julia Newton-Bishop,Alexander J. Stratigos,Hubert Pehamberger,Alexander M.M. Eggermont +11 more
TL;DR: Therapeutic decisions in stage IV patients should be primarily made by an interdisciplinary oncology team ('Tumour Board'), based on systematic literature reviews and experts' experience.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies,Philippe Saiag,Caroline Robert,Jean-Jacques Grob,Keith T. Flaherty,Ana Arance,Vanna Chiarion-Sileni,Luc Thomas,Thierry Lesimple,Laurent Mortier,Stergios J. Moschos,David Hogg,Ivan Marquez-Rodas,Michele Del Vecchio,Céleste Lebbé,Nicolas Meyer,Ying Zhang,Yingjie Huang,Bijoyesh Mookerjee,Georgina V. Long +19 more
TL;DR: Results from the phase 2 COMBI-MB trial provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases.
Journal ArticleDOI
Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests.
TL;DR: For experienced users, dermoscopy is more accurate than clinical examination for the diagnosis of melanoma in a pigmented skin lesion.
Journal ArticleDOI
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Marie-Françoise Avril,Steinar Aamdal,Jean-Jacques Grob,Axel Hauschild,Peter Mohr,Jean Jacques Bonerandi,Michael Weichenthal,K. Neuber,T. Bieber,K. Gilde,V. Guillem Porta,J. Fra,J. Bonneterre,Philippe Saiag,D. Kamanabrou,Hubert Pehamberger,J. Sufliarsky,J. L.Gonzalez Larriba,A. Scherrer,Y. Menu +19 more
TL;DR: ORR was higher in the fotemustine arm compared to the DTIC arm in first-line treatment of disseminated melanoma, and a trend in favor of fotamustine in terms of overall survival and time to BM was evidenced.